QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
F13-16 |
||
(Address of principal executive offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-half of one redeemable warrant |
||||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
☒ | Smaller reporting company | |||||
Emerging growth company |
Page |
||||||
Item 1. |
1 |
|||||
2 |
||||||
3 |
||||||
4 |
||||||
5 |
||||||
Item 2. |
17 |
|||||
Item 3. |
19 |
|||||
Item 4. |
20 |
|||||
Item 1. |
21 |
|||||
Item 1A. |
21 |
|||||
Item 2. |
21 |
|||||
Item 3. |
21 |
|||||
Item 4. |
21 |
|||||
Item 5. |
21 |
|||||
Item 6. |
22 |
|||||
23 |
September 30, 2021 |
||||
ASSETS |
||||
Current assets: |
||||
Cash |
$ | |||
|
|
|||
Total current assets |
||||
Deferred offering costs associated with proposed public offering |
||||
|
|
|||
Total assets |
$ | |||
|
|
|||
LIABILITIES AND SHAREHOLDER’S DEFICIT |
||||
Current liabilities: |
||||
Accounts payable |
$ | |||
Accrued offering and formation costs |
||||
Promissory note payable - related party |
||||
|
|
|||
Total current liabilities |
||||
|
|
|
|
|
Commitments and Contingencies (Note 5) |
|
|
|
|
Shareholder’s Deficit: |
||||
Preference shares, $ |
||||
Class A ordinary shares, $ |
||||
Class B ordinary shares, $ (1)(2) |
||||
Additional paid-in capital |
||||
Accumulated deficit |
( |
) | ||
|
|
|||
Total shareholder’s deficit |
( |
) | ||
|
|
|||
Total Liabilities and Shareholder’s Deficit |
$ |
|||
|
|
(1) | This number includes an aggregate of up to ). On November 15, 2021, the underwriters fully exercised their over-allotment option; thus, these shares are |
(2) | On September 17, 2021, our sponsor effected a surrender of |
For the three months ended September 30, 2021 |
For the period from March 5, 2021 (inception) through September 30, 2021 |
|||||||
Formation costs |
$ |
$ |
||||||
|
|
|
|
|||||
Net loss |
$ |
( |
) |
$ |
( |
) | ||
|
|
|
|
|||||
Weighted average shares outstanding, basic and diluted (1)(2) |
||||||||
|
|
|
|
|||||
Basic and diluted net loss per share |
$ |
( |
) |
$ |
( |
) | ||
|
|
|
|
(1) | This number excludes an aggregate of up to ). On November 15, 2021, the underwriters fully exercised their over-allotment option; thus, these shares are |
(2) | On September 17, 2021, our sponsor effected a surrender of |
Ordinary Shares |
Additional |
Total |
||||||||||||||||||
Class B |
Paid-In |
Accumulated |
Shareholder’s |
|||||||||||||||||
Shares |
Amount |
Capital |
Deficit |
Deficit |
||||||||||||||||
Balance as of March 5, 2021 (inception) |
$ | $ | $ | $ | ||||||||||||||||
Issuance of ordinary shares to Sponsor (1)(2) |
— | |||||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance as of June 30, 2021 |
( |
) |
( |
) | ||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance as of September 30, 2021 |
$ |
$ |
$ |
( |
) |
$ |
( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|
(1) | This number includes an aggregate of up to ). On November 15, 2021, the underwriters fully exercised their over-allotment option; thus, these shares are |
(2) | On September 17, 2021, our sponsor effected a surrender of |
For the period from March 5, 2021 (inception) through September 30, 2021 |
||||
Cash Flows from Operating Activities: |
||||
Net loss |
$ | ( |
) | |
Adjustments to reconcile net loss to net cash used in operating activities: |
||||
Formation costs funded by note payable through Sponsor |
||||
Formation costs paid in exchange for issuance of ordinary shares |
||||
Changes in operating assets and liabilities: |
||||
Accounts payable |
||||
Accrued offering and formation costs |
||||
|
|
|||
Net cash used in operating activities |
( |
) | ||
|
|
|||
Cash Flows from Financing Activities: |
||||
Proceeds from promissory note payable - related party |
||||
Repayment of promissory note payable - related party |
( |
) | ||
Offering costs paid |
( |
) | ||
|
|
|||
Net cash provided by financing activities |
||||
|
|
|||
Net increase in cash |
||||
Cash - beginning of period |
||||
|
|
|||
Cash - end of period |
$ | |||
|
|
|||
Supplemental disclosure of noncash investing and financing activities: |
||||
Deferred offering costs included in accounts payable |
$ | |||
|
|
|||
Deferred offering costs included in accrued offering and formation costs |
$ | |||
|
|
|||
Deferred offering costs paid through promissory note - related party |
$ | |||
|
|
|||
Issuance of Founder Shares in exchange for payment of deferred offering costs |
$ | |||
|
|
Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |
Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |
Level 3: | Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
• | in whole and not in part; |
• | at a price of $ |
• | upon a minimum of |
• | if, and only if the last reported sale price of Class A ordinary shares for any |
• | in whole and not in part; |
• | at a price of $ |
• | if, and only if the Reference Value equals or exceeds $10.00 per share (as adjusted); and |
• | if, and only if the Reference Value is less than $ |
No. |
Description of Exhibit | |
31.1 | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | |
32.1 | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
101.INS | Inline XBRL Instance Document | |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document | |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
WORLDWIDE WEBB ACQUISITION CORP. | ||||||
Date: December 6, 2021 | /s/ Daniel S. Webb | |||||
Name: | Daniel S. Webb | |||||
Title: | Chief Executive Officer and Chief Financial Officer |